Argenx Se (ARGX) Other Non-Current Assets (2016 - 2025)
Argenx Se (ARGX) posted Other Non-Current Assets of $52.0 million for Q4 2025, down 99.89% on a QoQ basis from $46.7 billion in Q2 2025, and up 22.64% year-over-year from $42.4 million in Q4 2024.
Argenx Se (ARGX) Other Non-Current Assets (2016 - 2025) Analysis & Trends
Argenx Se's Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $52.0 million for Q4 2025.
- Quarterly Other Non-Current Assets rose 22.64% year-over-year to $52.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $52.0 million (up 22.64% YoY) and the FY2025 annual result came in at $52.0 million, up 22.64% from the prior year.
- Other Non-Current Assets was $52.0 million for Q4 2025 at Argenx Se, down from $46.7 billion in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $46.7 billion in Q2 2025 and bottomed at $1.4 million in Q2 2021.
- A 5-year average of $4.7 billion and a median of $41.6 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets declined 25.48% — and 2025, when it surged 136097.34%.
- Argenx Se's Other Non-Current Assets stood at $54.9 million in 2021, then dropped by 25.48% to $40.9 million in 2022, then dropped by 3.01% to $39.7 million in 2023, then advanced by 6.89% to $42.4 million in 2024, then gained by 22.64% to $52.0 million in 2025.
- Business Quant data shows ARGX's Other Non-Current Assets at $52.0 million in Q4 2025, $46.7 billion in Q2 2025, and $42.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 14.48 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 63.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.99 Mn |
| Jun 30, 2025 | 46.68 Bn |
| Dec 31, 2024 | 42.39 Mn |
| Jun 30, 2024 | 34.28 Mn |
| Dec 31, 2023 | 39.66 Mn |
| Jun 30, 2023 | 39.23 Mn |
| Dec 31, 2022 | 40.89 Mn |
| Jun 30, 2022 | 43.10 Mn |
| Dec 31, 2021 | 54.88 Mn |
| Jun 30, 2021 | 1.44 Mn |
| Dec 31, 2020 | 1.48 Mn |
| Jun 30, 2020 | 696,122.80 |
| Dec 31, 2019 | 697,339.23 |
| Jun 30, 2019 | 400,015.52 |
| Dec 31, 2018 | 287,631.90 |
| Dec 31, 2017 | 301,422.73 |
| Jun 30, 2017 | 268,290.03 |
| Dec 31, 2016 | 1.24 Mn |